Registro:

Referencias:

• Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics (2011) CA Cancer J Clin, 61, pp. 69-90
• Karin, M., Nuclear factor-kappaB in cancer development and progression (2006) Nature, 441, pp. 431-436
• Mercader, M., Bodner, B.K., Moser, M.T., Kwon, P.S., Park, E.S., Manecke, R.G., T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer (2001) Proc Natl Acad Sci USA, 98, pp. 14565-14570
• Ammirante, M., Luo, J.L., Grivennikov, S., Nedospasov, S., Karin, M., B-cell-derived lymphotoxin promotes castration-resistant prostate cancer (2010) Nature, 464, pp. 302-305
• Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T., Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model (2010) Cancer Res, 70, pp. 1606-1615
• Matsuoka, T., Narumiya, S., The roles of prostanoids in infection and sickness behaviors (2008) J Infect Chemother, 14, pp. 270-278
• Hull, M.A., Ko, S.C., Hawcroft, G., Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer (2004) Mol Cancer Ther, 3, pp. 1031-1039
• Attard, G., Reid, A.H., Olmos, D., De Bono, J.S., Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven (2009) Cancer Res, 69, pp. 4937-4940
• Bonkhoff, H., Berges, R., From pathogenesis to prevention of castration resistant prostate cancer (2010) Prostate, 70, pp. 100-112
• Bonkhoff, H., Berges, R., The evolving role of oestrogens and their receptors in the development and progression of prostate cancer (2009) Eur Urol, 55, pp. 533-542
• Dutt, S.S., Gao, A.C., Molecular mechanisms of castration-resistant prostate cancer progression (2009) Future Oncol, 5, pp. 1403-1413
• Khandrika, L., Kumar, B., Koul, S., Maroni, P., Koul, H.K., Oxidative stress in prostate cancer (2009) Cancer Lett, 282, pp. 125-136
• Chetram, M.A., Odero-Marah, V., Hinton, C.V., Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells (2011) Mol Cancer Res, 9, pp. 90-102
• Vandercappellen, J., Van Damme, J., Struyf, S., The role of CXC chemokines and their receptors in cancer (2008) Cancer Lett, 267, pp. 226-244
• Thobe, M.N., Clark, R.J., Bainer, R.O., Prasad, S.M., Rinker-Schaeffer, C.W., From prostate to bone: Key players in prostate cancer bone metastasis (2011) Cancers (Basel, 3, pp. 478-493
• Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., Involvement of chemokine receptors in breast cancer metastasis (2001) Nature, 410, pp. 50-56
• Wang, J., Loberg, R., Taichman, R.S., The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis (2006) Cancer Metastasis Rev, 25, pp. 573-587
• Chinni, S.R., Sivalogan, S., Dong, Z., Filho, J.C., Deng, X., Bonfil, R.D., CXCL12/CXCR4 Signaling Activates Akt-1 and MMP-9
• Expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12 (2006) Prostate, 66, pp. 32-48
• Taichman, R.S., Cooper, C., Keller, E.T., Pienta, K.J., Taichman, N.S., McCauley, L.K., Use of the Stromal Cell-Derived Factor-1/CXCR4
• Pathway in prostate cancer metastasis to bone (2002) Cancer Res, 62, pp. 1832-1837
• Shulby, S.A., Dolloff, N.G., Stearns, M.E., Meucci, O., Fatatis, A., CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells (2004) Cancer Res, 64, pp. 4693-4698
• Kukreja, P., Abdel-Mageed, A.B., Mondal, D., Liu, K., Agrawal, K.C., Up-regulation of CXCR4 expression in PC-3 cells by stromalderived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: Role of MEK/ERK signaling pathway-dependent NF-kappaB activation (2005) Cancer Res, 65, pp. 9891-9898
• Engl, T., Relja, B., Marian, D., Blumenberg, C., Muller, I., Beecken, W.D., CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins (2006) Neoplasia, 8, pp. 290-301
• Sun, Y.X., Fang, M., Wang, J., Cooper, C.R., Pienta, K.J., Taichman, R.S., Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells (2007) Prostate, 67, pp. 61-73
• Xing, Y., Liu, M., Du, Y., Qu, F., Li, Y., Zhang, Q., Tumor cellspecific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach (2008) Cancer Biol Ther, 7, pp. 1839-1848
• Frigo, D.E., Sherk, A.B., Wittmann, B.M., Norris, J.D., Wang, Q., Joseph, J.D., Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro (2009) Mol Endocrinol, 23, pp. 1385-1396
• Cai, J., Kandagatla, P., Singareddy, R., Kropinski, A., Sheng, S., Cher, M.L., Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells (2010) Transl Oncol, 3, pp. 195-203
• Gopalan, A., Leversha, M.A., Satagopan, J.M., Zhou, Q., Al-Ahmadie, H.A., Fine, S.W., TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy (2009) Cancer Res, 69, pp. 1400-1406
• Toubaji, A., Albadine, R., Meeker, A.K., Isaacs, W.B., Lotan, T., Haffner, M.C., Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas (2011) Mod Pathol, 24, pp. 1511-1520
• Akashi, T., Koizumi, K., Tsuneyama, K., Saiki, I., Takano, Y., Fuse, H., Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer (2008) Cancer Sci, 99, pp. 539-542
• Begley, L.A., MacDonald, J.W., Day, M.L., Macoska, J.A., CXCL12
• Activates a robust transcriptional response in human prostate epithelial cells (2007) J Biol Chem, 282, pp. 26767-26774
• Wang, J., Shiozawa, Y., Wang, Y., Jung, Y., Pienta, K.J., Mehra, R., The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer (2008) J Biol Chem, 283, pp. 4283-4294
• Burns, J.M., Summers, B.C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development (2006) J Exp Med, 203, pp. 2201-2213
• Raggo, C., Ruhl, R., McAllister, S., Koon, H., Dezube, B.J., Fruh, K., Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus (2005) Cancer Res, 65, pp. 5084-5095
• Miao, Z., Luker, K.E., Summers, B.C., Berahovich, R., Bhojani, M.S., Rehemtulla, A., CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature (2007) Proc Natl Acad Sci USA, 104, pp. 15735-15740
• Singh, R.K., Lokeshwar, B.L., The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth (2011) Cancer Res, 71, pp. 3268-3277
• Lehrer, S., Diamond, E.J., Mamkine, B., Stone, N.N., Stock, R.G., Serum interleukin-8 is elevated in men with prostate cancer and bone metastases (2004) Technol Cancer Res Treat, 3, p. 411
• Wang, J., Lu, Y., Koch, A.E., Zhang, J., Taichman, R.S., CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway (2008) Cancer Res, 68, pp. 10367-10376
• Ha, H.K., Lee, W., Park, H.J., Lee, S.D., Lee, J.Z., Chung, M.K., Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer (2011) Mol Med Report, 4, pp. 419-424
• Chandrasekar, B., Bysani, S., Mummidi, S., CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation (2004) J Biol Chem, 279, pp. 3188-3196
• Deng, L., Chen, N., Li, Y., Zheng, H., Lei, Q., CXCR6/CXCL16
• (2010) Biochim Biophys Acta, 1806, pp. 42-49. , Functions As A Regulator In Metastasis And Progression Of Cancer
• Nakayama, T., Hieshima, K., Izawa, D., Tatsumi, Y., Kanamaru, A., Yoshie, O., Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues (2003) J Immunol, 170, pp. 1136-1140
• Inoue, K., Slaton, J.W., Eve, B.Y., Kim, S.J., Perrotte, P., Balbay, M.D., Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer (2000) Clin Cancer Res, 6, pp. 2104-2119
• Kim, S.J., Uehara, H., Karashima, T., McCarty, M., Shih, N., Fidler, I.J., Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice (2001) Neoplasia, 3, pp. 33-42
• Lamont, K.R., Tindall, D.J., Minireview: Alternative activation pathways for the androgen receptor in prostate cancer (2011) Mol Endocrinol, 25, pp. 897-907
• Waugh, D.J., Wilson, C., The interleukin-8 pathway in cancer (2008) Clin Cancer Res, 14, pp. 6735-6741
• McCarron, S.L., Edwards, S., Evans, P.R., Gibbs, R., Dearnaley, D.P., Dowe, A., Influence of cytokine gene polymorphisms on the development of prostate cancer (2002) Cancer Res, 62, pp. 3369-3372
• Wilson, C., Purcell, C., Seaton, A., Oladipo, O., Maxwell, P.J., O'Sullivan, J.M., Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis (2008) J Pharmacol Exp Ther, 327, pp. 746-759
• Tassidis, H., Culig, Z., Wingren, A.G., Harkonen, P., Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells (2010) Prostate, 70, pp. 1491-1500
• Shariat, S.F., Andrews, B., Kattan, M.W., Kim, J., Wheeler, T.M., Slawin, K.M., Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis (2001) Urology, 58, pp. 1008-1015
• Blaszczyk, N., Masri, B.A., Mawji, N.R., Ueda, T., McAlinden, G., Duncan, C.P., Osteoblast-derived factors induce androgenindependent proliferation and expression of prostate-specific antigen in human prostate cancer cells (2004) Clin Cancer Res, 10, pp. 1860-1869
• Culig, Z., Steiner, H., Bartsch, G., Hobisch, A., Interleukin-6
• Regulation of prostate cancer cell growth (2005) J Cell Biochem, 95, pp. 497-505
• Ishiguro, H., Akimoto, K., Nagashima, Y., Kojima, Y., Sasaki, T., Ishiguro-Imagawa, Y., APKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 (2009) Proc Natl Acad Sci USA, 106, pp. 16369-16374
• Malinowska, K., Neuwirt, H., Cavarretta, I.T., Bektic, J., Steiner, H., Dietrich, H., Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor (2009) Endocr Relat Cancer, 16, pp. 155-169
• Chun, J.Y., Nadiminty, N., Dutt, S., Lou, W., Yang, J.C., Kung, H.J., Interleukin-6 regulates androgen synthesis in prostate cancer cells (2009) Clin Cancer Res, 15, pp. 4815-4822
• Wu, Y., Zhou, B.P., TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion (2010) Br J Cancer, 102, pp. 639-644
• Davis, J.S., Nastiuk, K.L., Krolewski, J.J., TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable (2011) Mol Endocrinol, 25, pp. 611-620
• Shukla, S., MacLennan, G.T., Fu, P., Patel, J., Marengo, S.R., Resnick, M.I., Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression (2004) Neoplasia, 6, pp. 390-400
• Jin, R.J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth (2008) Cancer Res, 68, pp. 6762-6769
• Huang, S., Pettaway, C.A., Uehara, H., Bucana, C.D., Fidler, I.J., Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis (2001) Oncogene, 20, pp. 4188-4197
• Gasparian, A.V., Yao, Y.J., Kowalczyk, D., Lyakh, L.A., Karseladze, A., Slaga, T.J., The role of IKK in constitutive activation of NFkappaB transcription factor in prostate carcinoma cells (2002) J Cell Sci, 115, pp. 141-151
• Hanahan, D., Weinberg, R.A., Hallmarks of cancer: The next generation (2011) Cell, 144, pp. 646-674
• Mantovani, A., Cancer: Inflaming metastasis (2009) Nature, 457, pp. 36-37
• Shiota, M., Yokomizo, A., Tada, Y., Inokuchi, J., Kashiwagi, E., Masubuchi, D., Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression (2010) Oncogene, 29, pp. 237-250
• Maynard, S., Schurman, S.H., Harboe, C., De Souza-Pinto, N.C., Bohr, V.A., Base excision repair of oxidative DNA damage and association with cancer and aging (2009) Carcinogenesis, 30, pp. 2-10
• Taplin, M.E., Rajeshkumar, B., Halabi, S., Werner, C.P., Woda, B.A., Picus, J., Androgen receptor mutations in androgenindependent prostate cancer: Cancer and Leukemia Group B Study 9663 (2003) J Clin Oncol, 21, pp. 2673-2678
• Linja, M.J., Savinainen, K.J., Saramaki, O.R., Tammela, T.L., Vessella, R.L., Visakorpi, T., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer (2001) Cancer Res, 61, pp. 3550-3555
• Murakami, S., Noguchi, T., Takeda, K., Ichijo, H., Stress signaling in cancer (2007) Cancer Sci, 98, pp. 1521-1527
• Gort, E.H., Van Haaften, G., Verlaan, I., Groot, A.J., Plasterk, R.H., Shvarts, A., The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha (2008) Oncogene, 27, pp. 1501-1510
• Hoek, K., Rimm, D.L., Williams, K.R., Zhao, H., Ariyan, S., Lin, A., Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas (2004) Cancer Res, 64, pp. 5270-5282
• Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis (2004) Cell, 117, pp. 927-939
• Bostwick, D.G., Alexander, E.E., Singh, R., Shan, A., Qian, J., Santella, R.M., Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer (2000) Cancer, 89, pp. 123-134
• Best, C.J., Gillespie, J.W., Yi, Y., Chandramouli, G.V., Perlmutter, M.A., Gathright, Y., Molecular alterations in primary prostate cancer after androgen ablation therapy (2005) Clin Cancer Res, 11, pp. 6823-6834
• Sharifi, N., Hurt, E.M., Thomas, S.B., Farrar, W.L., Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: Implications for castration-resistant prostate cancer (2008) Clin Cancer Res, 14, pp. 6073-6080
• Tam, N.N., Gao, Y., Leung, Y.K., Ho, S.M., Androgenic regulation of oxidative stress in the rat prostate: Involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth (2003) Am J Pathol, 163, pp. 2513-2522
• Pang, S.T., Dillner, K., Wu, X., Pousette, A., Norstedt, G., Flores-Morales, A., Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress (2002) Endocrinology, 143, pp. 4897-4906
• Eliceiri, B.P., Integrin and growth factor receptor crosstalk (2001) Circ Res, 89, pp. 1104-1110
• Verma, I.M., Stevenson, J.K., Schwarz, E.M., Van Antwerp, D., Miyamoto, S., Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation (1995) Genes Dev, 9, pp. 2723-2735
• Karin, M., Cao, Y., Greten, F.R., Li, Z.W., NF-kappaB in cancer: From innocent bystander to major culprit (2002) Nat Rev Cancer, 2, pp. 301-310
• Kong, D., Li, Y., Wang, Z., Banerjee, S., Sarkar, F.H., Inhibition of angiogenesis and invasion by 3,30-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer (2007) Cancer Res, 67, pp. 3310-3319
• Ryter, S.W., Choi, A.M., Heme oxygenase-1: Molecular mechanisms of gene expression in oxygen-related stress (2002) Antioxid Redox Signal, 4, pp. 625-632
• Min, K.J., Lee, J.T., Joe, E.H., Kwon, T.K., An IkappaBalpha phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-kappaB-independent mechanism (2011) Cell Signal, 23, pp. 1505-1513
• Sacca, P., Meiss, R., Casas, G., Mazza, O., Calvo, J.C., Navone, N., Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer (2007) Br J Cancer, 97, pp. 1683-1689
• Lin, Q., Weis, S., Yang, G., Weng, Y.H., Helston, R., Rish, K., Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress (2007) J Biol Chem, 282, pp. 20621-20633
• Lin, Q.S., Weis, S., Yang, G., Zhuang, T., Abate, A., Dennery, P.A., Catalytic inactive heme oxygenase-1 protein regulates its own expression in oxidative stress (2008) Free Radic Biol Med, 44, pp. 847-855
• Gueron, G., De Siervi, A., Ferrando, M., Salierno, M., De Luca, P., Elguero, B., Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells (2009) Mol Cancer Res, 7, pp. 1745-1755
• Ferrando, M., Gueron, G., Elguero, B., Giudice, J., Salles, A., Leskow, F.C., Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer (2011) Angiogenesis, 14, pp. 467-479
• Li, Y., Su, J., DingZhang, X., Zhang, J., Yoshimoto, M., Liu, S., PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome (2011) J Pathol, (224), pp. 90-100
• Akech, J., Wixted, J.J., Bedard, K., Van Der Deen, M., Hussain, S., Guise, T.A., Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions (2010) Oncogene, (29), pp. 811-821
• Guise, T.A., Mohammad, K.S., Clines, G., Stebbins, E.G., Wong, D.H., Higgins, L.S., Basic mechanisms responsible for osteolytic and osteoblastic bone metastases (2006) Clin Cancer Res, 12, pp. 6213s-6216s
• Armstrong, A.P., Miller, R.E., Jones, J.C., Zhang, J., Keller, E.T., Dougall, W.C., RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes (2008) Prostate, 68, pp. 92-104
• Bendre, M.S., Margulies, A.G., Walser, B., Akel, N.S., Bhattacharrya, S., Skinner, R.A., Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway (2005) Cancer Res, 65, pp. 11001-11009
• Araki, S., Omori, Y., Lyn, D., Singh, R.K., Meinbach, D.M., Sandman, Y., Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer (2007) Cancer Res, 67, pp. 6854-6862
• Li, Z.G., Yang, J., Vazquez, E.S., Rose, D., Vakar-Lopez, F., Mathew, P., Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone (2008) Oncogene, 27, pp. 596-603
• Clines, G.A., Mohammad, K.S., Bao, Y., Stephens, O.W., Suva, L.J., Shaughnessy Jr., J.D., Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation (2007) Mol Endocrinol, 21, pp. 486-498
• Hall, C.L., Kang, S., MacDougald, O.A., Keller, E.T., Role of Wnts in prostate cancer bone metastases (2006) J Cell Biochem, 97, pp. 661-672
• Kingsley, L.A., Fournier, P.G., Chirgwin, J.M., Guise, T.A., Molecular biology of bone metastasis (2007) Mol Cancer Ther, 6, pp. 2609-2617
• Li, Z.G., Mathew, P., Yang, J., Starbuck, M.W., Zurita, A.J., Liu, J., Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms (2008) J Clin Invest, 118, pp. 2697-2710
• Deryugina, E.I., Quigley, J.P., Matrix metalloproteinases and tumor metastasis (2006) Cancer Metastasis Rev, 25, pp. 9-34
• Morgia, G., Falsaperla, M., Malaponte, G., Madonia, M., Indelicato, M., Travali, S., Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer (2005) Urol Res, 33, pp. 44-50
• Selvamurugan, N., Jefcoat, S.C., Kwok, S., Kowalewski, R., Tamasi, J.A., Partridge, N.C., Overexpression of Runx2 directed by the matrix metalloproteinase-13 promoter containing the AP-1 and Runx/RD/Cbfa sites alters bone remodeling in vivo (2006) J Cell Biochem, 99, pp. 545-557
• Pratap, J., Lian, J.B., Javed, A., Barnes, G.L., Van Wijnen, A.J., Stein, J.L., Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone (2006) Cancer Metastasis Rev, 25, pp. 589-600
• Dunn, L.K., Mohammad, K.S., Fournier, P.G., McKenna, C.R., Davis, H.W., Niewolna, M., Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment (2009) Plos One, 4, pp. e6896
• Yang, Q., McHugh, K.P., Patntirapong, S., Gu, X., Wunderlich, L., Hauschka, P.V., VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin (2008) Matrix Biol, 27, pp. 589-599
• Dai, J., Kitagawa, Y., Zhang, J., Yao, Z., Mizokami, A., Cheng, S., Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein (2004) Cancer Res, 64, pp. 994-999
• Weilbaecher, K.N., Guise, T.A., McCauley, L.K., Cancer to bone: A fatal attraction (2011) Nat Rev Cancer, 11, pp. 411-425
• Drake, J.M., Danke, J.R., Henry, M.D., Bone-specific growth inhibition of prostate cancer metastasis by atrasentan (2010) Cancer Biol Ther, 9, pp. 607-614
• Fontana, A., Galli, L., Fioravanti, A., Orlandi, P., Galli, C., Landi, L., Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer (2009) Clin Cancer Res, 15, pp. 4954-4962
• Wang, Z., Li, Y., Banerjee, S., Kong, D., Ahmad, A., Nogueira, V., Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways (2010) J Cell Biochem, 109, pp. 726-736
• Zayzafoon, M., Abdulkadir, S.A., McDonald, J.M., Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines (2004) J Biol Chem, 279, pp. 3662-3670
• Santagata, S., Demichelis, F., Riva, A., Varambally, S., Hofer, M.D., Kutok, J.L., JAGGED1 expression is associated with prostate cancer metastasis and recurrence (2004) Cancer Res, 64, pp. 6854-6857
• Bin Hafeez, B., Adhami, V.M., Asim, M., Siddiqui, I.A., Bhat, K.M., Zhong, W., Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator (2009) Clin Cancer Res, 15, pp. 452-459
• Pazolli, E., Luo, X., Brehm, S., Carbery, K., Chung, J.J., Prior, J.L., Senescent stromal-derived osteopontin promotes preneoplastic cell growth (2009) Cancer Res, 69, pp. 1230-1239
• McAllister, S.S., Gifford, A.M., Greiner, A.L., Kelleher, S.P., Saelzler, M.P., Ince, T.A., Systemic endocrine instigation of indolent tumor growth requires osteopontin (2008) Cell, 133, pp. 994-1005
• Anborgh, P.H., Mutrie, J.C., Tuck, A.B., Chambers, A.F., Role of the metastasis-promoting protein osteopontin in the tumour microenvironment (2010) J Cell Mol Med, 14, pp. 2037-2044
• Lynch, C.C., Hikosaka, A., Acuff, H.B., Martin, M.D., Kawai, N., Singh, R.K., MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL (2005) Cancer Cell, 7, pp. 485-496
• Li, X., Loberg, R., Liao, J., Ying, C., Snyder, L.A., Pienta, K.J., A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone (2009) Cancer Res, 69, pp. 1685-1692
• Zhang, Y., Forootan, S.S., Kamalian, L., Bao, Z.Z., Malki, M.I., Foster, C.S., Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression (2011) Int J Oncol, 38, pp. 1083-1091

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------